Mirum Pharmaceuticals (NASDAQ:MIRM) Now Covered by Analysts at Guggenheim

Share on StockTwits

Guggenheim initiated coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research note released on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $18.00 target price on the stock.

Separately, Evercore ISI began coverage on shares of Mirum Pharmaceuticals in a research report on Monday. They set an outperform rating and a $25.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, Mirum Pharmaceuticals currently has an average rating of Buy and an average price target of $25.00.

Shares of MIRM stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a fifty-two week low of $12.05 and a fifty-two week high of $15.50.

In other Mirum Pharmaceuticals news, major shareholder Holdings A/S Novo purchased 575,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 22nd. The shares were purchased at an average cost of $15.00 per share, with a total value of $8,625,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick J. Heron purchased 450,000 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 22nd. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $6,750,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,357,000 shares of company stock worth $20,355,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Recommended Story: Equal Weight Rating

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lundin Mining Co.  Insider Nemesia S.a.r.l.  Acquires 150,000 Shares
Lundin Mining Co. Insider Nemesia S.a.r.l. Acquires 150,000 Shares
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc  Stock
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc Stock
Osisko gold royalties Ltd  Director Sells C$897,627.00 in Stock
Osisko gold royalties Ltd Director Sells C$897,627.00 in Stock
Deciphera Pharmaceuticals Inc  Director Sells $917,325.00 in Stock
Deciphera Pharmaceuticals Inc Director Sells $917,325.00 in Stock
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc  Stock
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc Stock


© 2006-2019 Ticker Report